Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-352-4150
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees57
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Forty Seven (NASDAQ:FTSV) Frequently Asked Questions
What is Forty Seven's stock symbol?
Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."
How were Forty Seven's earnings last quarter?
Forty Seven Inc (NASDAQ:FTSV) posted its earnings results on Monday, May, 13th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.14. View Forty Seven's Earnings History.
When is Forty Seven's next earnings date?
What price target have analysts set for FTSV?
8 analysts have issued twelve-month price targets for Forty Seven's shares. Their forecasts range from $21.00 to $36.00. On average, they anticipate Forty Seven's share price to reach $27.7143 in the next year. This suggests a possible upside of 126.6% from the stock's current price. View Analyst Price Targets for Forty Seven.
What is the consensus analysts' recommendation for Forty Seven?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.
What are Wall Street analysts saying about Forty Seven stock?
Here are some recent quotes from research analysts about Forty Seven stock:
- 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (5/14/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating on FTSV and our 12-month price target of $21.00 per share. We derive our price target based on a risk- based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate." (3/29/2019)
Has Forty Seven been receiving favorable news coverage?
News coverage about FTSV stock has been trending positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Forty Seven earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Forty Seven's key competitors?
Some companies that are related to Forty Seven include Madrigal Pharmaceuticals (MDGL), Innoviva (INVA), Endo International (ENDP), Heron Therapeutics (HRTX), Cambrex (CBM), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Apellis Pharmaceuticals (APLS), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), Turning Point Therapeutics (TPTX), Epizyme (EPZM) and Theravance Biopharma (TBPH).
What other stocks do shareholders of Forty Seven own?
Who are Forty Seven's key executives?
Forty Seven's management team includes the folowing people:
- Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
- Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
- Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
- Mr. Mark Chao, Founder & VP of Clinical Devel.
- Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.
When did Forty Seven IPO?
(FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.
Who are Forty Seven's major shareholders?
Forty Seven's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (12.65%), BlackRock Inc. (3.63%), Bourgeon Capital Management LLC (1.16%), FMR LLC (0.86%), JPMorgan Chase & Co. (0.82%) and Goldman Sachs Group Inc. (0.57%). Company insiders that own Forty Seven stock include Chris H Takimoto, Christopher J Schaepe, Irving Weissman, Lifesciences Iii LP Clarus, Mark Anthony Mccamish, Peter Nieh, Ravi Mhatre, Ravindra Majeti and Stefan A Dyckerhoff. View Institutional Ownership Trends for Forty Seven.
Which institutional investors are selling Forty Seven stock?
FTSV stock was sold by a variety of institutional investors in the last quarter, including Bourgeon Capital Management LLC, Wellington Management Group LLP, JPMorgan Chase & Co., FMR LLC and Wells Fargo & Company MN. Company insiders that have sold Forty Seven company stock in the last year include Chris H Takimoto, Irving Weissman, Mark Anthony Mccamish and Ravindra Majeti. View Insider Buying and Selling for Forty Seven.
Which institutional investors are buying Forty Seven stock?
FTSV stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Candriam Luxembourg S.C.A., Northern Trust Corp, Goldman Sachs Group Inc., Exane Asset Management, Altrinsic Global Advisors LLC, Rhumbline Advisers and Charles Schwab Investment Management Inc.. Company insiders that have bought Forty Seven stock in the last two years include Christopher J Schaepe, Lifesciences Iii LP Clarus, Peter Nieh, Ravi Mhatre and Stefan A Dyckerhoff. View Insider Buying and Selling for Forty Seven.
How do I buy shares of Forty Seven?
Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Forty Seven's stock price today?
One share of FTSV stock can currently be purchased for approximately $12.23.
How big of a company is Forty Seven?
Forty Seven has a market capitalization of $383.52 million. The company earns $-70,370,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Forty Seven employs 57 workers across the globe.
What is Forty Seven's official website?
How can I contact Forty Seven?
Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]
MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
